Design Therapeutics will present DT-168 program updates for Fuchs endothelial corneal dystrophy at Eyecelerator on May 2, 2025.
Quiver AI Summary
Design Therapeutics, Inc., a biotechnology company focused on treatments for genetic diseases, announced it will provide an update on its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) during the Eyecelerator event on May 2, 2025. The presentation will cover safety results from a Phase 1 trial of DT-168, a GeneTAC® eye drop designed to target the TCF4 gene responsible for FECD. CEO Pratik Shah expressed optimism about DT-168's potential to restore endothelial function, which could represent a major advancement since current treatments for FECD are limited. The Eyecelerator conference emphasizes innovation in ophthalmology and aligns with the upcoming ARVO meeting in Salt Lake City.
Potential Positives
- Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy (FECD).
- DT-168, as a potentially innovative GeneTAC® small molecule eye drop, could represent a significant advancement in treating a disease currently without disease-modifying treatments.
- The presentation at Eyecelerator, an important forum in ophthalmology, enhances the company's visibility and credibility within the eye care industry.
- The opportunity to correlate the presentation with the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting could facilitate valuable networking and exposure to potential collaborators and investors.
Potential Negatives
- The press release highlights that there are currently no available disease-modifying treatments for Fuchs endothelial corneal dystrophy, emphasizing the seriousness and lack of options for patients, which might raise concerns about the viability of the company's treatments.
- The reliance on forward-looking statements introduces significant uncertainty regarding the actual efficacy and safety of DT-168, which could impact investor confidence and market perception.
- The press release mentions various risks and uncertainties that could materially affect the company's development plans, creating potential red flags for stakeholders regarding future success.
FAQ
What is the DT-168 program about?
The DT-168 program develops a GeneTAC® eye drop targeting genetic causes of Fuchs endothelial corneal dystrophy (FECD).
When will the DT-168 program update be presented?
The update on DT-168 will be presented on May 2, 2025, at Eyecelerator @ Park City.
What are the Phase 1 trial results for DT-168?
The Phase 1 trial results include safety findings from trials conducted in healthy adult volunteers.
What is Fuchs endothelial corneal dystrophy (FECD)?
FECD is a progressive corneal disease that leads to corneal transplant surgery when untreated.
How does DT-168 aim to help FECD patients?
DT-168 seeks to reduce the expression of the mutant gene product that causes endothelial cell dysfunction.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DSGN Insider Trading Activity
$DSGN insiders have traded $DSGN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $DSGN stock by insiders over the last 6 months:
- DEEPA PRASAD sold 3,806 shares for an estimated $23,863
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$DSGN Hedge Fund Activity
We have seen 45 institutional investors add shares of $DSGN stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRIEHAUS CAPITAL MANAGEMENT LLC added 776,082 shares (+inf%) to their portfolio in Q4 2024, for an estimated $4,788,425
- MPM BIOIMPACT LLC added 559,547 shares (+inf%) to their portfolio in Q4 2024, for an estimated $3,452,404
- CITADEL ADVISORS LLC added 383,243 shares (+66.6%) to their portfolio in Q4 2024, for an estimated $2,364,609
- ECOR1 CAPITAL, LLC added 372,849 shares (+692.6%) to their portfolio in Q4 2024, for an estimated $2,300,478
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. removed 343,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,116,310
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 262,010 shares (-93.5%) from their portfolio in Q4 2024, for an estimated $1,616,601
- POINT72 ASSET MANAGEMENT, L.P. added 256,010 shares (+16.0%) to their portfolio in Q4 2024, for an estimated $1,579,581
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m. MT in Park City, UT. The presentation will include safety findings from the Phase 1 single- and multiple-ascending dose trial of DT-168 in healthy adult volunteers and plans for Phase 2 clinical development in FECD patients.
DT-168 is a GeneTAC® small molecule, formulated as an eye drop, that is designed to selectively target the CTG repeat expansion in the TCF4 gene and reduce the expression of the mutant gene product that causes corneal endothelial cell dysfunction leading to FECD.
“We are pleased for the opportunity to showcase our Phase 1 results for DT-168 at Eyecelerator, a forum dedicated to highlighting innovation in the field of ophthalmology,” said Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics. “FECD is a progressive corneal disease with no disease-modifying treatments currently available, ultimately leading to corneal transplant surgery for many patients. We believe DT-168, formulated as an eye drop, has the potential to restore endothelial function, representing a significant advancement in the treatment of FECD.”
Eyecelerator conferences, backed by the American Academy of Ophthalmology, highlight industry advancements and innovative new products disrupting eye care. Eyecelerator @ Park City 2025 is adjacent to the Association for Research in Vision and Ophthalmology (ARVO) meeting being held May 4 - 8, 2025, in Salt Lake City, UT.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC
®
gene targeted chimera small molecules. The company’s GeneTAC
®
molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its GeneTAC
®
programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the potential for DT-168 to restore endothelial function and its impact on the treatment of FECD; Design's ability to advance its pipeline of GeneTAC
®
small molecules; and the capabilities and potential advantages of Design’s pipeline of GeneTAC
®
small molecules. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “designed to,” “anticipates,” “capable of,” “plans to,” “expects,” “estimate,” “intends,” “will,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Design’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with: the acceptance of INDs by the FDA or similar applications by foreign regulatory agencies for the conduct of planned clinical trials of our product candidates and our proposed design of future clinical trials; nonclinical development activities and results of nonclinical studies; conducting a clinical trial and patient enrollment, which are affected by many factors, and any difficulties or delays encountered with such clinical trial or patient enrollment may delay or otherwise adversely affect Design’s clinical development plans; the process of discovering and developing therapies that are safe and effective for use as human therapeutics and operating as a development stage company; undesirable side effects or other undesirable properties, which could cause Design or regulatory authorities to suspend or discontinue clinical trials and thereby delay or prevent Design’s product candidates’ development or regulatory approval; Design’s ability to develop, initiate or complete nonclinical studies and clinical trials for its product candidates; whether promising early research or clinical trials will demonstrate safety and/or efficacy in later nonclinical studies or clinical trials; changes in Design’s plans to develop its product candidates; reliance on third parties to successfully conduct clinical trials and nonclinical studies; competitive products, which may make any products we develop or seek to develop obsolete or noncompetitive; Design’s reliance on key third parties, including contract manufacturers and contract research organizations; Design’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; Design’s ability to obtain and maintain intellectual property protection for its product candidates; Design’s ability to recruit and retain key scientific or management personnel; and market conditions. For a more detailed discussion of these and other factors, please refer to Design’s filings with the Securities and Exchange Commission (SEC), including under the “Risk Factors” heading of Design’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC on March 10, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Design undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
